New test could predict leukemia relapse before it happens
NCT ID NCT01311258
Summary
This study is developing more sensitive blood tests to find tiny amounts of hidden cancer cells that remain after treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers want to see if these tests can identify patients who are at higher risk of their cancer returning. The goal is to better understand who might need different or additional treatment to prevent relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.